August 7, 2025，Sandoz has announced plans to acquire Just-Evotec Biologics’ site in Toulouse, France, as part of its strategy to enhance its in-house biosimilar development and manufacturing capabilities. The acquisition would enable Sandoz to utilize the facility for the production and development of its biosimilar portfolio, further strengthening its position in the competitive biosimilars market.
The Toulouse site, operated by Just-Evotec Biologics, is expected to play a key role in advancing Sandoz’s biosimilar pipeline. Biosimilars are biologic medical products that are highly similar to already approved reference products, offering more affordable treatment options. This move aligns with Sandoz’s broader efforts to expand its footprint in the biologics sector and meet growing global demand for cost-effective alternatives to branded biologics. Further details regarding the transaction or timeline have not been disclosed.